Urology · 5-alpha reductase inhibitorRegulatory Approvalcommercialnear-term

Aurobindo Pharma's Finasteride ANDA078341 Receives AP Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma25 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 6:31:04 AM

Assessment confidence: 69% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Aurobindo Pharma's receipt of Abbreviated Approval for Finasteride signifies increased competition in the urology market, which could impact pricing and market share dynamics. Portfolio teams must evaluate the implications of this entry on existing products and strategize accordingly. Regulatory context from FDA (FDA AP — FINASTERIDE (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Aurobindo's entry on pricing and market share for existing Finasteride products. The strongest clinical anchor is Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov), sponsor/company relevance (novartis). In Urology · 5-alpha reductase inhibitor, 7 regulatory and 5 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection (Humanexa Signals) — mechanism alignment (io ); sponsor/company relevance (roche). Secondary pressure from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis. This approval allows Aurobindo to enter the market for Finasteride, increasing competition among generic manufacturers in the urology space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — FINASTERIDE (SUPPL) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). The approval status indicates compliance with FDA standards, but does not introduce significant regulatory changes for the market.

Key Opportunities

The entry of Aurobindo Pharma into the Finasteride market could lead to price reductions and shifts in market share among existing competitors, affecting revenue streams.
Upside for Aurobindo Pharma may improve if Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Aurobindo Pharma may improve if PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Aurobindo Pharma may improve if Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of Aurobindo's entry on pricing and market share for existing Finasteride products.

What Would Change This Assessment

This becomes more urgent if Monitor for the launch timeline and any potential market responses from competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (finasteride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (finasteride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (finasteride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (finasteride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection
Humanexa Signalshigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS
Humanexa Signalsmedium relevance
Moderate corpus alignment
Sandoz Receives FDA Approval for Liraglutide ANDA212972
Humanexa Signalsmedium relevance
Moderate corpus alignment

Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Finasteride
generic manufacturers

Commercial impact

medium

The entry of Aurobindo Pharma into the Finasteride market could lead to price reductions and shifts in market share among existing competitors, affecting revenue streams.

Regulatory impact

low

The approval status indicates compliance with FDA standards, but does not introduce significant regulatory changes for the market.

What to watch

Monitor for the launch timeline and any potential market responses from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.